PHAT Projected Dividend Yield
Phathom Pharmaceuticals Inc ( NASDAQ : PHAT )Phathom Pharmaceuticals, Inc. is a biopharmaceutical company. Co. is focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases. Co.'s pipeline product candidate, VOQUEZNA, VOQUEZNA TRIPLE PAK, and VOQUEZNA DUAL PAK. Its product candidate, VOQUEZNA, contains vonoprazan, an oral small molecule potassium-competitive acid blocker (PCAB). PCABs are a novel class of medicines that block acid secretion in the stomach. Vonoprazan has also demonstrated clinical benefits in the treatment of erosive gastroesophageal reflux disease (erosive GERD), and in combination with antibiotics for the treatment of Helicobacter pylori (H. pylori) infection. 21 YEAR PERFORMANCE RESULTS |
PHAT Dividend History Detail PHAT Dividend News PHAT Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |